Pharmaceutical Unit Integral To Growth Strategy: Merck KGaA
Published: Jan 22, 2014
Merck KGaA (MRK) is committed to its pharmaceutical business after failing to deliver new medicines as expected, Chief Executive Officer Karl-Ludwig Kley said. New products to treat cancer should yield concrete results in the next 12 to 18 months, and the early-stage pipeline of medicines in development could pay off in three years or more, he said in an interview yesterday at the World Economic Forum in Davos, Switzerland. “The pharma business is an integral part of our strategy going forward,” said Kley, 62, who has been CEO of the family-controlled company since 2007.
Help employers find you! Check out all the jobs and post your resume.